The innovative application of autologous biofillers in aesthetic dermatology

Amiri, Rezvan; Khalili, Maryam; Iranmanesh, Behzad; Ahramiyanpour, Najmeh; Karvar, Mehran; Aflatoonian, Mahin

doi:10.23736/s2784-8671.23.07485-6

Cited by 1 publication

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, IGF-1, FGF, EGF, and VEGF bind to specific receptors on the surface of epithelial cells, fibroblasts, endothelial cells, and mesenchymal cells and may result in overexpression of genes and proteins involved in suppressing melanogenesis and tissue regeneration. [ 3 13 14 ]…”

Section: Discussionmentioning

confidence: 99%

“…PRP can release various types of growth factors through α-granules of platelets including epidermal growth factor (EGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-I), platelet-derived growth factor (PDGF), and transforming growth factor-beta (TGF-β). [ 2 3 4 5 ] Plasma rich in growth factors (PRGF) is another plasma-derived product that differs from PRP in several aspects. First, in the process of obtaining PRGF, calcium chloride is used as an anticoagulant instead of thrombin, thus forming a fibrinous mesh with gelatinous consistency.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combination of Plasma Rich in Growth Factors With Topical 4% Hydroquinone Compared With Topical 4% Hydroquinone Alone in the Treatment of Dermal Type of Melasma: A Single-Blinded Randomized Split-Face Study

Amiri,

Karimi Maskooni,

Farsinejad

et al. 2024

Indian Dermatology Online Journal

View full text Add to dashboard Cite

Background: Response to the current available treatments of melasma, dermal type, in particular, is usually gradual and can result in possible side effects. Aim and Objectives: In this study, we aim to evaluate the efficacy of the combination of plasma rich in growth factors (PRGF) and topical 4% hydroquinone (HQ) in comparison with monotherapy using topical 4% HQ alone in the treatment of dermal type of melasma. Materials and Methods: This is a single-blinded, randomized, split-face clinical trial on twenty female patients with dermal type of melasma. Patients were asked to apply topical 4% HQ on both sides of their face at night for 6 months. In each participant, one side of the face was randomly chosen to receive monthly intradermal injections of PRGF for 3 sessions. Efficacy of the treatment was assessed using hemi melasma area and severity index (MASI) score, physician’s global assessment (PGA), and patients’ global assessment (PtGA). Results: Both groups revealed significant improvement in hemi-MASI score during the treatment course. Mean percentage of improvement at the end of study was 40.38 ± 6.04% and 33.42 ± 3.23% in the combination therapy and monotherapy groups, respectively (P = 0.31). PGA demonstrated excellent-to-marked improvement in melasma in 25% and 5% of patients in the combination therapy and monotherapy groups, respectively (P = 0.31). PtGA showed high levels of satisfaction in 15% of patients in the combination therapy group (vs. 0% in the monotherapy group) (P = 0.05). Conclusion: Differences between the two treatment groups in terms of hemi-MASI and PGA scores were not statistically significant; however, patients demonstrated higher satisfaction with combination of PRGF and topical 4% HQ compared with topical HQ alone. Thereby, combination of PRGF and topical 4% HQ can be suggested as a safe alternative therapeutic approach and may hold promise in the development of future therapeutic options for dermal type of melasma.

show abstract

Section: Discussionmentioning

confidence: 99%